PRIN settore LS1 codice 2020LW7XWH "Early Phase Preclinical Development of PACECOR, a Mutation-Independent Anti-SARS-Co2 Therapeutic Strategy" (DFM.AD004.324)
Thematic area
Physical sciences and technologies of matter
Project area
Sistemi e materiali complessi, materia soffice, biofisica e reti (DFM.AD004)Structure responsible for the research project
Institute of nanoscience (NANO)
Project manager
GIORGIA BRANCOLINI
Phone number: 0592055311
Email: giorgia.brancolini@cnr.it
Abstract
The proposed project is an integrated effort towards the prevention of infective spread of the SARS-CoV-2 virus and related viruses. To approach such challenge, the study will exploit the amalgamation of transversal competences, spanning from physical chemistry and bioinformatics to biomedicine, such as to warrant the operational multidisciplinary nature of the endeavours needed to take upon the various phases of the research programme. It is axiomatic that virus entrance into target cells is a key step to abrogate for halting infection, preventing the subsequent viremia in the host and viral dissemination. Current approaches in this direction have been biased towards targeting the virus, most conveniently
through the generation of specific immunological tools. However, an alternative approach could be todevise tolerable and highly selective pharmacological probes aimed at obstructing ancillary components of the virus-host interaction, whille desensitising the impact of genotypic changes of the virus.
Goals
The proposed project is an integrated effort towards the prevention of infective spread of the SARS-CoV-2 virus and related viruses. To approach such challenge, the study will exploit the amalgamation of transversal competences, spanning from physical chemistry and bioinformatics to biomedicine, such as to warrant the operational multidisciplinary nature of the endeavours needed to take upon the various phases of the research programme. It is axiomatic that virus entrance into target cells is a key step to abrogate for halting infection, preventing the subsequent viremia in the host and viral dissemination. Current approaches in this direction have been biased towards targeting the virus, most conveniently
through the generation of specific immunological tools. However, an alternative approach could be todevise tolerable and highly selective pharmacological probes aimed at obstructing ancillary components of the virus-host interaction, whille desensitising the impact of genotypic changes of the virus.
Start date of activity
25/04/2022
Keywords
pacecor, strategia terapeutica, anti-SARS-Co2
Last update: 24/03/2025